General practitioner engagement with the Scottish National Naloxone Programme: A needs assessment project. by Pflanz-Sinclair, Christine et al.
General Practitioner Engagement 
with the Scottish National 
Naloxone Programme: 
A Needs Assessment Project 
January 2013
Ms Christiane Pflanz-Sinclair, 
Dr Catriona Matheson, and  
Dr Lorna Aucott ; 
University of Aberdeen 
On behalf of The GP Naloxone 
Research Team
The opinions expressed in this publication are 
those of the author/s and do not necessarily 
reflect those of NHS Health Scotland.
© NHS Health Scotland 2013
www.healthscotland.com
We are happy to consider requests for other  
languages or formats. Please contact 0131 536 5500  
or email nhs.healthscotland-alternativeformats@nhs.net
i 
 
 
Contents 
 
List of Tables and Figures ........................................................................... ii 
Acknowledgements .................................................................................... iii 
Abbreviations ............................................................................................. iv 
Executive Summary .................................................................................... v 
1. Introduction......................................................................................... 1 
1.1 Background ........................................................................................................... 1 
1.2 Aims and Objectives .............................................................................................. 5 
2. Method ............................................................................................... 6 
2.1 Methodology .......................................................................................................... 6 
2.2 Survey of GP Knowledge, Experience and Views on Engagement in the National 
Programme ..................................................................................................................... 6 
2.3 Qualitative Interview Study .................................................................................... 7 
2.4 Ethical Approval .................................................................................................... 8 
2.5 Problems and Solutions ......................................................................................... 8 
3. Results ............................................................................................. 10 
3.1 Survey Results .................................................................................................... 10 
3.2 Telephone Interview Findings .............................................................................. 20 
4. Discussion ........................................................................................ 39 
4.1 Summary ............................................................................................................. 39 
4.2 Strengths and Weaknesses ................................................................................. 39 
4.3 Consideration of Key Findings ............................................................................. 40 
4.4 Policy Implications ............................................................................................... 45 
5. Conclusions ...................................................................................... 46 
5.1 Conclusion ........................................................................................................... 46 
5.2 Issues for Consideration ...................................................................................... 46 
6. References ....................................................................................... 48 
  
ii 
 
List of Tables and Figures 
Table 1: Sample Characteristics 
Table 2: Current Practice Relating to Drug Misuse 
Table 3: Drug-Related Deaths (DRDs) 
Table 4: Involvement in the national programme 
Table 5: Importance of factors in relation to extending the national programme  
Table 6: Attitudes (%) concerning the distribution of Naloxone. 
Table 7: Drug dependency training  
Table 8: DRD prevention training delivery 
Table 9a: Recognised Specialist Training with Currently Treat 
Table 9b: Location with Currently Treat 
Table 9c: Recognised Specialist Training with Location  
Table 10: Gender associations with prescribing and explaining to patients  
Table 11: Gender with importance of factors to extend the programme 
Table 12: Prepared to prescribe and explain to a patient with training 
Table 13: Prepared to prescribe and explain to a patient and family/friends 
Table 14: Interviewee Demographics 
 
Figure 1: Gender with proportion Currently Treating 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Acknowledgements  
We, the research team, would like to thank Mrs. Hazel Riley, University of Aberdeen for 
transcribing the interviews and performing data entry and Natasha Pflanz for 
administrating the survey.  We would also like to thank Amanda Laird and Dr Saket 
Priyadarshi for their contribution to questionnaire development, Amanda Cardy and her 
SPCRN colleagues for their efforts in recruiting GPs for interviews, and the RCGP, in 
particular Shelley Ell, for contacting specialist GPs. 
 
We would also like to thank the Naloxone GP Research Project Steering Group 
(Andrew McAuley, Elinor Dickie, Phil Eaglesham, Stephen Malloy and Kirsten 
Horsburgh), hereafter referred to as the Steering Group, for all their support and input.  
Finally, we would like to thank all the individual GPs who took the time to participate in 
this research either by completing a questionnaire or participating in an interview.   
iv 
 
Abbreviations 
 
ADP  Alcohol and Drug Partnerships 
BLS  Basic Life Support 
CPR  Cardio Pulmonary Resuscitation 
DRD  Drug-Related Death 
ER  Emergency Room 
GP  General Practitioner 
ISD  Information Services Division 
NES  NHS Education for Scotland 
NFDRD National Forum on Drug Related Deaths  
NHS  National Health Service 
PI  Principal Investigator  
PG  Post Graduate  
QOF  Quality and Outcomes Framework 
RCGP  Royal College of General Practitioners  
R & D  Research and Development  
SDF  Scottish Drugs Forum 
SPCRN Scottish Primary Care Research Network 
SPSS  Statistical Product and Service Solutions 
v 
 
Executive Summary 
Background 
The Scottish National Naloxone Programme was launched in November 2010 following 
successful pilots in Scottish sites.  The aim of the programme is to reduce Scotland’s 
high number of drug-related deaths (DRDs) caused by opiate overdose.  The national 
programme is currently being implemented through specialist drug services.  However, 
there may be drug users who are not using such services or have limited access to 
such services.  General Practitioners (GPs) are likely to have direct contact with drug 
using patients who are on opiate replacement treatment or receiving general medical 
care.  Thus, GPs are in an ideal position to either, direct these patients to Naloxone 
training and supply schemes, or to provide this service themselves.  Additionally, they 
will often be in contact with friends and family of drug users who may be registered at 
the same practice; this group is a vital part of the national programme as they potentially 
would be the ones to administer Naloxone, thus ‘buying’ time for an ambulance to 
arrive. 
 
This needs assessment was commissioned to ensure GPs’ views and knowledge are 
considered to maximise engagement of GPs in the Scottish National Naloxone 
Programme. 
 
Aims and objectives  
 
The overall aim of this project was to identify at a national level the best ways to enable 
GPs to engage effectively with the Scottish National Naloxone Programme.  The 
specific objectives were: 
 
1. To determine current GP knowledge, awareness and attitudes in relation to take-
home Naloxone through a nationally representative survey; 
 
2. To describe the needs of GPs in relation to take-home Naloxone and their 
involvement in the national programme through qualitative interviews; 
 
3. To identify barriers to the delivery of current/proposed models of care from 
survey and interview responses; 
4. To identify enablers to the delivery of current/proposed models of care from 
survey and interview responses; 
5. To highlight the perceived workforce development requirements from survey and 
qualitative responses; 
6. To identify and report on the policy implications of the study overall. 
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Method 
 
The study used mixed methods comprising a quantitative, postal survey and qualitative 
telephone interviews.  The postal survey was sent to a representative sample of 500 
GPs across Scotland.  An initial mailing of the four page questionnaire was followed by 
a postal reminder.  A reduced one page questionnaire containing key questions was 
posted as a final reminder.  Telephone interviews were conducted with a purposive 
sample of GPs across Scotland covering a range of experience of working with drug 
users and involvement with Naloxone. 
 
 
Summary of key results 
 
The survey achieved a response rate of 55% (240/439): 183 GPs completed the long 
questionnaire and a further 57 completed the short questionnaire (61 questionnaires did 
not reach intended addresses). 
 
This research identified some awareness of the Naloxone programme but very low 
current levels of involvement by GPs sampled (3.3%), 9% currently provided routine 
overdose prevention, there was little involvement in distributing information (<20%) and 
few survey respondents knew who their local Naloxone lead was (8%).  However there 
was tentative willingness to be involved in Naloxone prescribing with half of respondents 
willing to provide this to drug users or their friends/family.  
 
Further analysis found those with some specialised drug treatment training would be 
more willing to prescribe Naloxone to drug users. 
 
When asked what might enable the expansion of the national programme into primary 
care, the respondents rated the following factors as ‘very important’: ‘having supporting 
evidence’ 89.7%; ‘appropriate GP training’ 82.8%; ‘it must be on the local formulary’ 
67.2%; that ‘practice nurses should be trained’ 52.3%; ‘GPs should be paid’ 43.5%; ‘it 
should be part of the Quality and Outcomes Framework’ 14.7%.  From interviews it 
became apparent that GPs were not really aware of what primary care Naloxone 
provision may involve. 
 
The preferred mode of training GPs on DRD prevention was locally delivered (45.8%) 
followed by online resources (32.3%). 
 
Models of DRD prevention for GPs, including Naloxone prescribing, were explored in 
interviews and the possibility of opportunistic intervention seemed to be “off their radar”. 
Almost as a default response, many GP respondents considered that current practice of 
specialist services delivering Naloxone as part of current shared care arrangements 
seemed to be the preferred choice.  Further comments made in interviews and written 
comments as to why some people are not prepared to prescribe Naloxone suggested 
attitudinal barriers towards drug users more generally. 
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Discussion and conclusion  
 
Both interviews and the survey indicated that GPs did not currently feel sufficiently 
skilled or knowledgeable to be involved in Naloxone training and provision.  There was 
a strong need evident for information on DRDs and associated risk factors, and on the 
prescribing and use of Naloxone, which should be evidence based.  A key barrier 
identified was the typecasting of Naloxone prescribing as a specialist service that only 
specialists should provide. Negative attitudes to drug users generally were evident and 
this potential stigmatisation of drug users as a patient group should be reviewed. 
 
In conclusion, this research identified minimal awareness among GPs of the national 
programme.  GPs tend to classify Naloxone distribution as a specialist service and 
therefore assume it is not part of their remit.  Even those with higher involvement or 
specialist training in substance misuse considered this a service that is not necessarily 
relevant to them.  However, there were tentative and encouraging signs that GPs would 
be willing to be more involved in Naloxone distribution if certain enablers were 
addressed.  Most important of these was training, which should be evidence based, and 
which was recognised by GP respondents as essential. 
 
Issues for consideration  
 
Training for GPs is essential prior to expanding the national programme into General 
Practice. 
 
Specific training Issues 
1.  A range of training and information resources should be available to meet the mixed 
needs of GPs.  Both online resources and local evening training sessions are essential. 
 
2.  Targeted training through visits by national programme trainers to practices that are 
not part of a shared care scheme, but situated in areas of known drug use, may be 
required. 
 
3. Negative attitudes towards drug users generally must be addressed to overcome the 
potential stigmatisation of this group. Further research is required to test novel 
approaches to changing entrenched negative attitudes.   
 
4.  All training should: 
a. assume a low level of knowledge of illicit drug use generally and Naloxone 
distribution and administration in particular, 
b. cover practical aspects of Naloxone administration (who, how, where), 
c. cover risk factors for DRDs, 
d. address expressed concerns (risky use of Naloxone/not phoning for an 
ambulance). 
 
viii 
 
 
Models of care 
5. Enhanced care of substance misuse should include running Naloxone training 
sessions for known drug users in that practice.  (This could include working with 
specialist services if part of a shared care scheme). 
 
6.  All GPs should be made aware that Naloxone packs can be prescribed/supplied to 
any drug user considered at risk on an opportunistic basis.  It must be emphasised this 
is not a specialist service. 
 
General 
7. Any communication, resources or training material for GPs regarding Naloxone 
distribution should emphasise: 
a. that this is a lifesaving medication, 
b. there is a good evidence base to support the national programme. 
 
8. An in depth exploration of the stigmatisation of drug users by GPs (and other 
generalist health professionals) is recommended to enable both the reduction in DRDs 
and recovery based drug strategy to be delivered.  
 
 
1. Introduction 
 
1.1 Background 
 
1.1.1 Drug-Related Deaths (DRDs) 
Definitions of DRDs can be complex but the simplest, as defined by the General 
Registrar for Scotland, was a death in which: 
 
“...the underlying cause is poisoning, drug abuse or drug dependence and where any of 
the substances controlled under the Misuse of Drugs Act (1971) are involved.”1  
 
The rate of DRDs in Scotland is the highest in the UK and one of the highest in Europe.2  
Rates have been increasing since 1997 and in 2008, 2009 and 2011 there were more 
than 500 (just under 500 in 2010).1  The majority of these deaths involve opiates, usually 
by injection and concurrent use of benzodiazepines and/or alcohol is common.  A 
number of other risk factors have been identified including: having a long history of drug 
use; recently released from prison; recently leaving a detoxification programme; newly 
started on opiate replacement treatment; psychological stress and homelessness.3   
 
A detailed analysis of DRDs in 2010 found that the majority of cases had died in a 
home; 53.3% in their own home and 26.9% in someone else’s.  There was someone 
present at the scene in 62.4% of cases and resuscitation had been attempted by a 
friend, witness, relative, spouse or partner in approximately a third of cases.4  
 
A National Forum on DRDs was established in 2005.  This independent group monitors 
data on DRDs and advises Government on how to address Scotland’s high rate of 
DRDs.  The Forum also considers possible interventions.  One intervention that had 
shown potential to be effective was that of take-home Naloxone.  A number of 
successful take-home Naloxone pilots/projects have been conducted across the globe to 
test the supply of take-home Naloxone to injecting drug users and their 
families/friends.5,6   
 
1.1.2 The Scottish National Naloxone Programme 
Naloxone is a short acting opiate antagonist that reverses the effects of an opiate 
overdose.  It has long been a staple supply of emergency medicine.  Although it can be 
administered intravenously and intra-nasally, it is most frequently administered through 
the intramuscular route and is not orally active.  The Scottish National Naloxone 
Programme (hereafter ‘the national programme’) was launched in November 2010 
following successful pilots in the Health Boards of Lanarkshire, Glasgow and latterly, 
Highland.6  The programme is centrally coordinated and funded by the Scottish 
Government, empowering individuals, families, friends and communities to reverse an 
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opiate overdose.  Naloxone provides more time for an ambulance to arrive and further 
treatment to be given to those in opiate overdose situations. 
 
The explicit aim of the programme is to reduce Scotland’s high and increasing number 
of DRDs caused by opiate overdose.  This was also noted as an important component 
of Scotland’s drugs strategy: The Road to Recovery.7  
 
Scotland is now in its third year of delivering the national programme, with 29 of the 30 
Alcohol and Drug Partnerships (ADP) now having developed local delivery models.  The 
Scottish Drugs Forum provides a programme of training and awareness to support local 
ADPs to deliver take-home Naloxone to those at risk.  Training programmes aim to raise 
awareness of DRDs and risks as well as training drug users and family members on 
Naloxone administration.  Naloxone administration training covers the specific 
instructions on how to intervene in an overdose emergency and how to administer First 
Aid, resuscitation and intra-muscular Naloxone.8 
 
Data on supply during 2011-12 indicate that 2730 Naloxone packs were supplied in the 
community of which 87% were supplied to individuals, 11% to service workers and 2% 
to friends and family of those at risk (with their consent).  Of these, 132 packs were to 
replace packs used on a person at risk of overdose. 9 
 
1.1.3 The role of primary care  
The engagement of General Practitioners is essential to maximise the benefit of the 
national programme.  Naloxone is currently largely being distributed through specialist 
drug services.  However, there may be drug users who are not using such services or 
perhaps, if in a rural location, may have limited access to such services.  Analysis of the 
2010 DRDs found that 62% of people had been in contact with drug treatment services 
prior to their death.  This leaves almost one third that had not and even those that had 
may not have had recent contact.4 Thus, primary care distribution is considered 
essential to enhance access to this life saving medication.  The potential involvement of 
GPs in DRD prevention is not a new concept.  Cullen et al. noted the importance of this 
in 2000.10 However, in the UK there has been little explicit work to explore this.  
Furthermore the changes to the GP contract in which GPs are encouraged to specialise 
may have proved counter-productive.  GPs general involvement in providing services to 
drug users has decreased in Scotland11 which may have impacted on involvement in 
DRD prevention work. 
 
Not all GPs manage patients with drug dependence as some refer them directly to 
specialist services.  However, all GPs should provide general medical care.  Analysis of 
DRDs in 2010 found that co-morbidity was common with over half of cases having a 
psychiatric condition and almost half having an alcohol problem.4  Furthermore, analysis 
of the causes of premature mortality in a cohort of drug users in Edinburgh found a 
range of co-morbid conditions including HIV/hepatitis C induced liver disease, kidney 
failure, respiratory disease and cardio-vascular disease.12  With this level of co-morbidity 
it is very likely that these drug users will have consulted their GP even if they are not 
seeing them in relation to management of their drug dependency.  Thus, GPs would be 
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in an ideal position to either point these patients to Naloxone administration training or 
provide this themselves.  Additionally, GPs will often be in contact with friends and 
family who may be registered at the same practice; this group is a vital part of the 
national programme as they potentially would be required to administer Naloxone, thus 
‘buying’ time for an ambulance to arrive. 
 
However, before extending the national programme into primary care, it is very 
important to consider GP’s current understanding, knowledge and willingness to be 
involved in DRD prevention and the national programme specifically.  Thus, a research 
project to inform the national programme implementation process was considered 
essential to ensure GPs’ perspectives are taken into account and to identify appropriate 
mechanisms for implementation, including training.   
 
1.1.4 Baseline activity/Level of engagement of General Practice 
To assess the level of GP engagement prior to the start of this commissioned research, 
a mapping exercise was conducted by NHS Health Scotland across 13 Health Boards in 
Scotland (excluding the Western Isles which has opted out of the national 
programme).13  This was conducted at Health Board level as GP services are managed 
at board level.  Local Health Board Naloxone coordinators1 were sent a short pro-forma 
that sought information on: 
 
• current levels of GP engagement/activity in relation to Naloxone;  
• any facilitators or barriers that may have been encountered; 
• whether there were any outcomes from such GPs’ current activity; and 
• what future plans exist for activity around GP engagement with the national 
programme.  
 
 
Responses were received from ten of the 13 local Health Board areas.  Findings 
revealed little active GP involvement in the direct supply of Naloxone.  Only one Health 
Board mentioned a GP that they knew supplied Naloxone.  Training in this case was not 
provided in general practice but by a third sector organisation.  Only one other Health 
Board provided local training on and/or the supply of Naloxone within the GP setting, but 
this was delivered by specialist substance misuse service staff.  
 
Two Health Board areas had no GP involvement and the reason given was because 
GPs in these areas had decided to opt out of all care of drug users.  Several Health 
Boards ran awareness raising events regarding Naloxone, some of which were well 
attended by GPs.  At the lower level of involvement several Health Boards mentioned 
that GPs were notified if a patient had been supplied with Naloxone.  Involvement of 
specialist services appeared to be a facilitator to GP engagement.  Several future 
awareness raising events were planned at Health Board level.  
 
                                            
1 Naloxone coordinators are the lead contact people in each NHS Health Board area. 
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The mapping exercise concluded that the current level of GP involvement with the 
national programme was low and that it appeared to be facilitated by an existing shared 
care service structure.13 
 
  
5 
 
 
1.2 Aims and objectives 
 
Aim:  
The overall aim of this project was to identify at a national level how to enable GPs to 
engage effectively with the Scottish National Naloxone Programme.  
 
 
Specific objectives: 
 
1. To determine current GP knowledge, awareness and attitudes in relation to take-
home Naloxone through a nationally representative survey; 
 
2. To describe the needs of GPs in relation to take-home Naloxone and their 
involvement in the national programme through qualitative interviews; 
 
3. To identify barriers to the delivery of current/proposed models of care from survey 
and interview responses; 
4. To identify enablers to the delivery of current/proposed models of care from 
survey and interview responses; 
5. To highlight the perceived workforce development requirements from survey and 
qualitative responses; and 
6. To identify and report on the policy implications of the study overall. 
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2. Method  
 
2.1 Methodology  
The study used mixed methods comprising a quantitative postal survey and qualitative 
telephone interviews.  Mixed methods gave both breadth and depth to the study and 
ensured a full assessment of the potential issues to be considered in taking the 
Naloxone GP engagement project forward.  Both strands of the study ran concurrently 
over the period of 1st August – 31st October 2012.  The postal survey and the 
qualitative interviews are presented separately below. 
 
2.2 Survey of GP knowledge, experience and views on engagement in the 
National Programme 
2.2.1 Questionnaire development  
A questionnaire was developed following discussions with the Steering Group and 
familiarisation with the policy documents and literature.  An initial draft was circulated 
around the Steering Group and the strategic project group which oversees the whole 
GP/Naloxone engagement programme.  This initial draft was six pages long.  Following 
revision and reduction to four pages (the maximum considered feasible based on the 
research team’s experience to encourage participation), a pre-pilot version of the 
questionnaire was completed by a convenience sample of four GPs.  The main issue 
raised was the length of the questionnaire; however it was felt difficult to further reduce 
the length without losing important content. 
 
The final questionnaire covered:  
 
• current practice relating to drug misuse generally;  
• knowledge of DRDs and risk factors; 
• awareness, attitudes and involvement in the national programme including factors 
that might influence GP involvement and views on different models of delivery;  
• training experience; 
• demographics, including the location of the practice i.e. whether city centre, 
suburban, town (defined as 4,000-90,000 inhabitants) or rural (defined as <4,000 
inhabitants). 
  
A copy of the questionnaire used in the survey is included in appendix 1. 
 
The sampling frame for the project was the general practice population currently working 
in Scotland.  A random sample was identified by the study statistician from the ISD 
database which lists all GPs in Scotland.  A 1 in 10 sample was identified, stratified by 
NHS area to ensure a geographical spread.  20 were used in the pilot sample and 500 
for the main distribution.  Prior to the main questionnaire mailing, a letter from Dr 
Laurence Gruer, Director of Public Health Sciences at NHS Health Scotland was sent to 
the sample.  This letter endorsed the national programme generally and specifically 
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noted and encouraged response to the questionnaire which followed approximately one 
week later. 
 
The questionnaire was piloted among 20 GPs.  The questionnaire was mailed with a 
reply paid envelope, an invitation letter and information sheet (appendix 2).  The 
purpose of the pilot was to identify any problems with distribution or the study materials.  
No changes were required from the pilot so the main distribution continued.  Pilot data 
were not included in the data analysis.  The main distribution was mailed the week of 
August 27, 2012.  A postal reminder was sent two weeks later.   
2.2.2 Data analysis 
Data was entered into an SPSS Statistics 20 database for analysis.  Simple descriptive 
statistics (frequencies and distributions) were calculated.  Cross tabulations were 
conducted for key variables.  These were cross tabulations of gender, years of 
experience as a GP, training of the GP (specialist vs. non specialist), geographical 
location of their practice and whether or not they are treating drug misusers against 
attitudes of risk factors in relation to DRDs and the involvement and knowledge of the 
national programme.  
2.2.3 Quality assurance 
A research assistant set up an SPSS database which was checked by the study 
Principle Investigator (PI) prior to any data being entered.  Questionnaire data were 
entered onto the SPSS database by the research assistant and research secretary.  
Data entry was checked by the statistician and by another researcher (20% of total 
checked).  Data for the short questionnaire was entered by the statistician and checked 
by another researcher. (Over 12% total check, see section 2.6) 
 
2.3 Qualitative interview study 
Interviews were conducted to elicit GPs’ views on how to engage the GP community in 
the national programme through prescribing and accompanying training of drug users in 
resuscitation and Naloxone administration.  Since it was desirable to have national 
coverage, it was considered most time-efficient to use telephone interviews.  
 
2.3.1 Topic guide development 
It is known that GPs are asked to take part in many interviews and surveys and 
therefore it was felt that a short interview was essential.  Thus, a short topic guide was 
developed with input from the Steering Group, seeking general views on GP 
involvement, barriers and enablers to involvement as well as some discussion around 
experience of Naloxone use and drug misuse treatment more generally.  A copy is 
attached in appendix 3. 
2.3.2 Sampling and recruitment of interviewees 
A purposive sample was used to cover a range of different levels of experience with 
drug misusers generally and Naloxone specifically as it was considered that this might 
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influence GPs’ views.  The research team aimed to recruit specialist GPs in substance 
misuse (four); prison GPs (four) and non-specialist GPs (12).   
 
One national specialist GP was recruited through the university research team and other 
specialist GPs were recruited through the RCGP specialist courses in substance 
misuse.  Prison GPs were recruited through the prison service, Scottish Primary Care 
Research Network (SPCRN) and NHS Health Scotland, and non-specialist GPs were 
recruited through SPCRN. 
 
Those identified as potential interviewees were contacted by e-mail and sent a study 
information sheet and invitation either by post or e-mail.  This was followed up by e-mail 
or a telephone call to arrange a suitable time for the interview. 
2.3.3 Interview conduct 
Interviews were conducted by telephone and tape recorded using specialist recording 
equipment.  Verbal consent was obtained prior to switching on the tape recording 
equipment.  Interviewees were also asked to initial, sign and return a consent form 
which had been posted to them prior to the interview.  Interviews lasted 15-20 minutes. 
2.3.4 Data management and analysis 
Interview recordings were transcribed.  A basic thematic analytical approach was used 
in which themes were identified and the range of views and experiences under those 
themes presented.  Due to the targeted nature of interviews and the limited time 
available for full in-depth qualitative analysis, the themes largely followed the topic guide 
headings although some analytical themes were also identified. 
2.3.5 Interview quality assurance 
Each transcript was checked for accuracy and references removed to protect anonymity.  
The first three interviews were listened to by another researcher and feedback given on 
interview conduct.   
2.4 Ethical approval 
NHS ethical approval was not required because this study involved health professionals 
only.  However NHS Research and Development approval was required as was ethical 
approval in the host University.  Ethical approval was sought and gained after minor 
amendments.  NHS R&D approval was sought and obtained without amendments being 
required. 
2.5 Problems and Solutions  
The research team encountered two problems during data collection.  The first problem 
related to the involvement of specialist GPs as a comparison group in the postal survey 
which was not possible due to data protection reasons.  Instead, all GPs who had 
attended a level two course RCGP course (n=308) were e-mailed and asked to contact 
the research team if they were willing to participate.  The response to this e-mail was 
very poor, thus no specialist comparison group was possible. 
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The second problem was in relation to a lower response rate to the postal questionnaire 
than was anticipated at the outset of the project.  This required an amendment to the 
study protocol.  Initially, when the response rate appeared to be slightly less than 
anticipated, telephone calls were made to practice managers to ensure the 
questionnaire had been received and to determine whether the named GP was still 
present at the practice.  This identified that a number of GPs had left, retired, or were on 
sick or maternity leave.  It was hoped these calls might act as a reminder.  However, this 
did not boost response as hoped and therefore it was decided to produce a one page 
version of the questionnaire to be sent in a third mailing.  The Steering Group and the 
university research team jointly decided which key questions were to be included from 
the existing questionnaire.  These were put into a one page questionnaire (appendix 4) 
and a new accompanying letter was developed (see appendix 5).  An amendment to the 
original ethics application was made to the University Ethics Board which was passed 
promptly within two weeks without changes being required.  The short version 
questionnaire was also anonymous to boost response.  This was posted in mid-October. 
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3. Results 
3.1  Survey results  
There were in total 183/439 responders to the long questionnaire.  The baseline was 
adjusted from 500 to account for 61 questionnaires that were returned because 
addressees did not receive the questionnaire for the following reasons: wrong address, 
maternity leave or sickness.  
 
An additional 57 (presumed previous non-responders) returned the short questionnaire 
(covering seven of the original questions prioritised as most important by the Steering 
Group and the university research team). Overall then for the most important questions 
there was a 55% response rate.  The different questionnaire forms will be initially 
investigated for the seven common questions.  Where there are major differences these 
will be further investigated otherwise the results will relate the combined dataset 
(n=240).   
3.1.1 Summary statistics 
3.1.1.1 Basic characteristics (Table 1) 
Just under half of all the respondents were men.  Most (75%) had been GPs for 10 or 
more years with some (13%) being qualified for no more than four years.  The largest 
proportion (43%) of GPs were based in Towns. 
 
Table 1: Sample Characteristics 
Male %:  
 
n=237 45.6% 
 
 
 
 
 
Years of 
experience as 
a GP: n=183 
≤4 5-9 10-19 20+ 
23 (12.6%) 22 (12.0%) 62 (33.9%) 76 (41.5%) 
Location  
n=236 
City Centre: Suburban: Town: Rural:  
54 (22.9%) 39 (16.5%) 101 (42.8%) 42 (17.8%) 
Location defined in method 
 
3.1.1.2 Current practice relating to drug misuse  
The proportion of GP’s currently treating for drug misuse was 47%.  The range of 
number of patients seen by each GP varied widely from 1 to as much as 72 in a month, 
but almost half stated they saw fewer than 5.  Similarly, the numbers of patients on 
maintenance programmes within their practice varied from 1 to 470, although about a 
third estimated this to be 6-20 patients and a further third to be at 21-50. Very few GPs 
(6.8%) were in dispensing practices.  (Table 2) 
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Table 2: Current Practice Relating to Drug Misuse 
Currently treat:  
n=239 
Yes:  47.3%  
Number of drug 
users YOU see: 
Range <5 6-10 11+ total  
1-72 37 
(48.1%) 
15 
(19.5%) 
25 
(32.5%) 
77  
 
Patients on a 
maintenance 
programme: 
Range <5 6-20 21-50 51+ total 
1-470 8 
(10.8%) 
25 
(33.8%) 
27 
(36.5%) 
14 
(18.9%) 
74 
Is yours a 
Dispensing 
Practice:  n=176 
 
Yes:  
 
6.8% 
 
 
3.1.2 Drug-Related Deaths (DRDs) 
Table 3 shows that just under half (42.6%) of the GPs stated that they did not know how 
many DRDs there are in Scotland annually.  Only 12% correctly identified the range of 
500-750 DRDs.  
 
Table 3: Drug-Related Deaths (DRDs) 
No. of 
DRDs 
n=183 
<100 100-250 250-500 500-750 >750 Don't 
Know 
4 
(2.2%) 
33 
(18.0%) 
35 
(19.1%) 
22 
(12.0%) 
11 
(6.0%) 
78  
(42.6%) 
  
Risk Factors (n=183)  
 
Agreed 
 
% 
D
R
D
 R
is
k 
fa
ct
or
s*
 
 
People who inject  167 91.3 
People recently released from prison   159 86.9 
People who take alcohol with other drugs 159 86.9 
People who take benzodiazepines with other drugs  137  74.9 
Homeless people 137 74.9 
Those newly started on opiate replacement  131 71.6 
People who’ve had additional psychological stress 129 70.5 
People who are under 24 years old † 111 60.7 
People who’ve recently been on a detox 
programme 
108 59.0 
People who’ve used illicit drug for a long time  104 56.8 
 
Do you provide overdose prevention:            n=177 
 
Yes: 9.0% 
* Ordered as per proportion, not as in questionnaire 
† This is not an actual risk factor 
 
Of the various potential risk factors, most GPs agreed that people who inject themselves 
are at high risk of overdosing followed by patients recently released from prison and 
those also consuming alcohol.   
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Only 9% of the respondents provided any overdose prevention service. 
3.1.3 The Scottish National Naloxone Programme  
Knowledge and practice about the national programme are summarised in Table 4.  
Only just over half of the respondents had heard of the national programme, mostly 
from NHS communications.  The majority did not have any display or other information 
about the programme within their practice – only 33 (18%) practices displayed some 
information, mostly posters and/or leaflets.  Very few knew who their local Naloxone 
lead was (8%) and even fewer had had any involvement with the national programme 
(3%).  Around half (55.2%) of the GPs surveyed knew where to refer drug users for 
Naloxone.  Similarly, 44% and 51% were prepared to prescribe Naloxone to patients 
and to patients’ families/friends respectively.  Those not prepared to prescribe were in 
general concerned about not having sufficient training/knowledge/experience or 
because their practice has decided not to provide services for drug users or because 
they felt the addictions team/specialist service should provide this service (see open 
question responses in appendix 7). 
 
Table 4: Involvement in the national programme 
Heard of national programme?:  n=240 Yes: 57.1% 
 
    If yes via  n=112
† 
Colleagues NHS Com: Other: 
26 (23.2%) 71 (63.4%) 31(27.7%) 
Display/give out infomation on 
Naloxone?   
n=181 Yes:   18.23% 
If yes how: n=33 
P 
12 
L 
7 
P/L 
8 
O 
5 
P/L/O 
1 
Know who local Naloxone lead is? n=182 Yes:     8.2% 
Involved with national programme? n=181 Yes:     3.3% 
Know where to refer for Naloxone? n=181 Yes:    55.2% 
Prepared to prescribe & explain 
Naloxone to patients at risk?  
 
n=237 
Yes:  
43.9% 
No: 
22.4% 
Unsure: 
33.8% 
Prepared to prescribe Naloxone & 
explain to family /friend?  
 
n=182 
 
50.5% 
 
22.0% 
 
27.5% 
NHS Com: NHS communications; † Of the 137 who had heard of the program only 112 specified how they had heard of national 
programme- these were all independent questions and should be treated independently.  
P: poster only; L: leaflets only; O: other only; P/L: poster & leaflets P/L/O: poster, leaflets & other  
 
GPs were asked about various factors that might facilitate extending the national 
programme in primary care (Table 5).  Training was noted as being important, especially 
for GPs.  Most agreed that the programme needed to be evidence based and two thirds 
(67%) thought it should be on the local formulary, but perhaps not in the QOF (57% 
stated this to be ‘Not Important’). There was a mixed response as to whether GPs 
should be paid for the service.   
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Table 5: Importance of factors in relation to extending the national programme  
Factors * Very 
Important 
Somewhat 
Important 
Not 
Important 
n 
Have supporting Evidence   89.7% 9.5% 0.9% 232 
 
GP appropriate training         82.8% 14.2% 3.0% 233 
 
Must be on local formulary   67.2% 24.6% 8.2% 232 
 Practice Nurses appropriate training   52.3% 30.6% 17.1% 222 
GP paid for service   43.5% 39.7% 16.8% 232 
 Should be included in the QOF  † 14.7% 28.4% 56.9% 225 
 † QOF: Quality and outcome Framework.  Recall responses differed between questionnaire formats 
* Ordering with respect to importance not as per questionnaire 
 
Within the long questionnaire, GPs were offered a choice of two potential delivery 
models for the national programme.  Most of the responding GPs, 158/170 (92.9%), 
selected Model Two (GPs will only prescribe and others will deliver Basic Life Support 
(BLS) and Naloxone training) as their preferred choice – rather than Model One 
(delivering the whole intervention).  However, it should be noted that 13 GPs, 7% of the 
sample, did not give valid responses to this question. 
 
Of those who selected Model Two and gave further responses (n=158), the person they 
felt should deliver the patient training component of the intervention was generally not 
the GP (only 11% in favour), or the practice nurse (favoured by 25%) but mostly by 
some other professional (69%) including community psychiatric nurses, specialist 
(drugs) nurses or a key worker.  
 
There were mixed views on how such an intervention should be delivered.  Of the 
responders, n=174, 35% thought it should be one-to-one, while 25% thought it should be 
in small groups and a further 40% had no preference. 
 
Approximately 60% (103/174) of those responding thought take-home Naloxone 
intervention sessions should be 20-30 minutes long, while 54/174 (31%) thought these 
should be more brief (<10 minutes).  However, of those preferring the brief intervention, 
responses were split with 24/52 (46%) considering that the intervention would best be 
delivered opportunistically, as opposed to by appointment.  
 
In terms of debriefing and re-supply once Naloxone had been used, the survey 
responders mainly thought GPs should be responsible, 99/180 (55%), followed by 
practice nurses, 24/180 (13.3%), but several, 71 (39.4%), cited others (the open 
questions in the survey showed that most interviewees believed that this should include 
an outside service, for example shared-cared clinics, substance misuse service or a 
psychiatric nurse). 
 
The participants were asked to indicate their attitudes towards a variety of issues 
concerning the distribution of Naloxone.  These, presented in Table 6, illustrate mixed 
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views: an uncertainty that General Practice distribution of Naloxone would reduce 
DRDs; more who disagreed that Naloxone might encourage riskier injecting practices; 
that peer group injecting of Naloxone might reduce seeking an ambulance; that 
Naloxone is a relatively important use of NHS resources but many being uncertain; and 
more uncertainty/disagreement about these GPs feeling confident in identifying and 
addressing overdose risks.  
 
Table 6: Attitudes (%) concerning the distribution of Naloxone. 
Statements 
 
 
 
n S
tro
ng
ly
 
ag
re
e 
A
gr
ee
 
U
nc
er
ta
in
 
D
is
ag
re
e 
S
tro
ng
ly
 
di
sa
gr
ee
 
I believe General Practice based 
distribution of Naloxone is essential 
to reduce DRDs. 
182 6.6 19.8 49.5 14.3 9.9 
       
I am concerned that giving injecting 
drug users Naloxone might 
encourage riskier injecting 
practices. 
183 5.5 20.9 24.7 37.9 11.0 
       
I am worried that if Naloxone is 
administered by a peer to an 
injecting drug user they might not 
phone for an ambulance. 
181 9.9 40.9 28.7 19.9 0.6 
       
I believe the National Naloxone 
Programme is an important use of 
NHS resources. 
181 5.5 40.3 44.8 6.6 2.8 
       
I feel confident in identifying and 
addressing overdose risks. 
182 2.7 21.4 37.4 34.1 4.4 
3.1.4 Training  
The GPs were asked various questions about whether they had ever received training 
for treating drug dependency.  Around one third of those who responded, 61/181 
(33.7%), stated that they had some previous specialist drug dependency training (Table 
7).  However, of this group, seven had not received a recognised training qualification*, 
leaving 29 GPs stating some recognised specialised training course (defined as RCGP 
1 and some local specialist service-run training programme) and a further 25 GPs giving 
details of more extensive training (for example RCGP 2, Credited Post graduate 
course). 
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Table 7: Drug dependency training  
n=181 Yes (%) 
No training specified 120 (66.3%) 
Specified some training   61 (33.7%) 
Training considered minimal/ not 
recognised* 
7 (11.5%) 
Some specialist training* 29 (47.5%) 
More specialist training* 25 (41.0%) 
*As defined by the authors. 
In contrast, very few, 8/180 (4.4%), have had any specific training on the prevention of 
DRDs.  However, those who had not any had such training were in the main, 84/128 
(65.6%), interested in receiving some.   
 
The final question about training was about how DRD prevention training should be 
delivered (Table 8).  Of those who responded, more favoured local evening sessions, 
although online resources were selected by about a third of respondents.   
 
Table 8: DRD prevention training delivery 
Mode of Training * n= 201 
Locally delivered evening training: (45.8%) 
Using Online resources: (32.3%) 
National forum e.g. RCGP: (3.0%) 
  Other:  (18.9%) 
* Ordered as per proportion, not as in questionnaire 
 
3.1.5 Comparisons of long and Short questionnaires  
The seven common questions were investigated for differences between the long and 
short forms of the questionnaire.  These are presented in Appendix 6.  Most did not 
differ between the two formats except for one question: 
 
‘Would you be prepared to prescribe Naloxone and explain its use to a patient at risk of 
opiate overdose?’  On inspection the difference was that more were ‘unsure’ for the 
short format compared to definitely ‘yes’ of the long format responders.    
 
Gender was not seen here to be statistically significant (p=0.086) between the long and 
short questionnaires (respectively 48.9% and 35% male).  However, the proportions 
themselves warrant that for further analysis with gender comparisons the effect of the 
different forms should be considered. 
 
3.1.6 Associations 
Several comparisons were highlighted as potentially important and determined prior to 
analysis as defined by the Steering Group.  These were differences between: gender, 
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experience, training of the responding GPs, the geographical location of their general 
practice and whether or not they currently treat drug users.  These were compared 
against GPs attitudes towards the ten risk factors relating to DRDs and questions about 
the national programme, specifically whether they would be prepared to prescribe and 
explain Naloxone to patients at risk, along with six attitudes towards several factors that 
might help extend the national programme.   
 
In addition to GPs being asked whether they would be prepared to prescribe and explain 
Naloxone to a patient at risk, they were also asked a similar question relating to family 
and friends of a patient.  It might be expected that these two questions would be closely 
associated and hence were also examined. 
 
Although all of the above were compared, only significant associations (gender and 
training) are highlighted in sections 3.1.6.2 and 3.1.6.3. 
 
3.1.6.1 Associations between pre-defined comparative variables 
Gender, Experience, Training, Location and Currently Treating were pre-defined 
comparative variables which were checked for confounding and contradictory 
associations.   
 
Overall, while the Male: Female ratio was even within this sample, as previously 
mentioned there were proportionately more women respondents, 35/54, for the short 
questionnaire.  While this was not significant, it did on inspection affect the association 
between Gender and Currently Treat (see Figure 1).  
 
 
Figure 1: Gender with proportion currently treating 
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For the long questionnaire, more men treated drug users whereas for the short 
questionnaire there were more women.  When the long and short questionnaires were 
combined, the results cancelled each other out.  A logistic regression was conducted. 
Whether or not respondents ‘currently treat’ drug users was dependent on gender and 
adjusted for questionnaire format.  This indicated significance for gender (p=0.008), 
questionnaire format (p=0.042) and the gender x questionnaire interaction (p=0.005).  
This suggested that women and those responding to the short questionnaire were 
independently less likely to treat drug users.  However, in combination a woman 
responding using the short questionnaire was more likely to be currently treating drug 
users. 
 
Specialist Training and Practice Location were both significantly associated with those 
Currently Treating drug users (Tables 9a and 9b) but not significantly with each other 
(Table 9c) despite the observed higher proportion of those with some specialist training 
being in city GP practices.  Those currently treating drug users were significantly more 
likely to be in the cities along with having had some recognised training.   
 
Table 9a: Recognised specialist training with ‘currently treat’ 
 Specialist Training (%) 
 None Some More n 
Currently Treat (%)‡  34.6 
 
86.2 
 
68.0 
 
47.5 
 
n  127 29 25 181 
‡ Pearson Chi-Squared, p<0.001 
 
Table 9b: Location with ‘currently treat’ 
  GP Location 
 City  Suburban Town Rural Total 
Currently Treat (%) ‡ 81.5 48.7 36.6 29.3 47.6 
n 54 39 101 41 235 
‡ Pearson Chi-Squared, p<0.001 
 
Table 9c: Recognised specialist training with location  
   Specialist Training † 
 None Some More n 
G
P 
Lo
ca
tio
n 
City Centre  51.3% 23.1% 25.6% 30 
Suburban 
 
69.0% 17.2% 13.8% 29 
Town 
 
79.7% 13.9% 6.3% 79 
Rural 
 
70.0% 13.3% 16.7% 30 
 Total 70.0% 16.4% 13.8% 177 
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 N 124 29 24  
†Pearson Chi-Squared, p=0.061 
 
These location/training/treating associations, while not surprising, will need to be 
considered when examining other associations. 
3.1.6.2 Gender 
With respect to DRDs, regardless of gender, GP’s generally agreed in their assessment 
of importance of the ten given risk factors (Table 3).  As these questions were very 
similar, the significance level was adjusted because there could have been a tendency 
to give the same response for all. Despite this, the risk factor of ‘psychological stress’ 
was highly significant (Continuity Correction Chi-Squared, p=0.002, n=182).  The result 
indicates that more female GPs (82%) considered such stress to be important in relation 
to increasing the risk of DRDs compared to male GPs (60%).   
 
Table 10: Gender associations with prescribing and explaining to patients  
 Yes No Unsure n p-value 
      ALL 104 (44.4%) 52 (22.2%) 78 (33.3%) 234  
Male 50 (46.3%) 31 (28.7%) 27 (25.0%) 108 0.017† 
Female 54 (42.9%) 21 (16.7%) 51 (40.5%) 91  
†Pearsons Chi-Square to test gender 
 
One of the questions common to both the long and short questionnaire was whether 
GPs would be prepared to prescribe Naloxone and explain its use to a patient at risk 
(Table 10).  Regardless of gender, about 44% were prepared to prescribe and explain to 
a patient.  However, of those who felt unable to prescribe, female GPs were significantly 
more likely to indicate that they were unsure while male GPs tended to be split between 
‘unsure’ and ‘no’.   
 
Views of the six factors (listed in Table 4) that might help extend the national programme 
in primary care were examined.  Gender responses varied for only two of these (Table 
11):  ‘GPs should be paid’ and Naloxone ‘must be on the local formulary’.  Significantly 
more women (89%) considered that GP’s should be paid for the service, to be 
‘very/some importance’ compared to 77% of men.  Similarly, 77% of female GPs thought 
it ‘very important’ that Naloxone must be on the local formulary compared to 56% of 
male GPs, a significantly higher proportion.   
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Table 11: Gender with importance of factors to extend the programme 
Factor Very 
important 
Somewhat 
important 
Not 
important 
n p-
value† 
G
Ps
 
Pa
id
 
ALL 43.7% 39.7% 16.6% 229  
Male 45.7% 31.4% 22.9% 105 p=.017 
Female 41.9% 46.8% 11.3% 124 
Lo
ca
l 
Fo
rm
ul
ar
y ALL 67.7% 24.5% 7.9% 229  
Male 56.2% 30.5% 13.3% 105 p=.001 
Female 77.4% 19.4% 3.2% 124 
† Pearson Chi-Square test 
 
 
3.1.6.3 Level of specialist training for treatment of drug dependency 
Responding GPs were in general agreement about most of the ten risk factors they were 
asked to consider in relation to DRDs and although there were some differences in 
responses depending on specialist training, (People who inject (p=0.012), People 
recently released from prison (p=0.013), People who have recently been on a detox 
programme (p=0.02)), these would not be considered significant if the p-values are 
adjusted to account for the identical structure of these questions.   
 
The level of training did influence willingness to prescribe and explain Naloxone to a 
patient.  Only n=219 answered this question from both the long and short 
questionnaires.  While 99 respondents (45%) were willing (Table 12), when broken 
down into level of training then significantly more (72%) of those with the higher levels 
were prepared to prescribe Naloxone to patients.  This was not significant for the 
question associated with prescribing/explaining to family/friends of patients. 
 
Table 12: Prepared to prescribe and explain to a patient with training 
Training Level N Yes % 
None 165 67 (40.6%) 
Some 29 14 (48.3%) 
More 25 18 (72.0%) 
Total 219 99 (45.2%) 
Chi-squared p=0.026 
 
3.1.6.4 Prepared to prescribe and explain Naloxone  
As seen earlier (Table 4) only around 50% of the GPs were prepared to prescribe and 
explain Naloxone to either the patient at risk or to the patients’ family/friends.  Table 13 
shows further that of those prepared to prescribe and explain to the patient, 91% would 
also be prepared to prescribe/explain to family/friends.  This was a significant trend 
20 
 
response such that their response to one would reliably determine their response to the 
other. 
 
Table 13: Prepared to prescribe and explain to a patient and family/friends 
Patient Family and Friends  
yes no Unsure Total 
Yes 79 (90.8%) 2 (2.3%) 6 (6.9%) 87 (48.6%) 
No 4 (10.0%) 33 (82.5%) 3 (7.5%) 40 (22.2%) 
unsure 7 (13.2%) 5 (9.4%) 41 (77.4%) 53 (29.4%) 
Total 90 (50.3%) 40 (22.1%) 50 (27.6%) 180 
Chi-Squared for Trend, p<0.001  
 
 
3.2 Telephone interview findings 
 
3.2.1 Interviewee demographics 
25 GPs were approached by email and asked if they would be willing to participate in an 
interview; none of them were part of the survey sample.  23 of the 25 initially agreed and 
in the end, 17 of them took part in an interview (Table 15).  One was a face-to-face 
interview and sixteen interviews were conducted over the telephone.  Demographics of 
the GPs that were interviewed are listed in table 14 below:  
 
Table 14: Interviewee demographics 
Gender  
Male 15 
Female  2 
Type of GP  
Prison GP  3 
Specialist GP  8 
Non-specialist GP  6 
Health Board  
Grampian  3 
Lothian  4 
Tayside  1 
Lanarkshire  1 
Greater Glasgow & Clyde  3 
Shetland  2 
Highland  2 
Dumfries & Galloway  1 
 
3.2.2  Interview data management and analysis 
Interviews lasted about 15-20 minutes and largely followed a predetermined topic guide. 
A basic thematic approach was used in which the following themes were identified: 
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• Experience with treating substance misuse patients and experience with 
Naloxone  
• Willingness to participate in the national programme 
• Resources 
• Opportunistic Naloxone 
• Models of delivery in practice 
• Barriers to Naloxone  
 
 
3.2.2.1 Experience with treating substance misuse patients and experience with 
Naloxone  
Each interviewee was asked about their involvement with substance misuse patients 
and their experience with Naloxone to establish a profile of experience in this area.  
 
Most interviewees have had some contact with substance misuse patients, either in 
previous posts or in their current position.  Approximately half of the interviewees have 
had experience with Naloxone as an opiate antagonist, one interviewee reported they 
had used Naloxone to treat multiple sclerosis (low dose naltrexone is used in this way) 
and two carry it in their medical bag for emergencies; one of the two makes use of it ‘at 
least once per year’ while the other has not used it once at the time of interview. 
3.2.2.2  Experience with treating substance misuse patients  
Most of the interviewees reported that they have had many years of experience in 
treating drug users, although two of them are now working at a practice which does not 
have any.  Another interviewee spent the last 11 years specifically working with 
homeless people which include: 
 
‘...a very high frequency of substance misuse problems....’ (2)  
 
One interviewee explained that while there were several drug users at his practice, he 
was not the first point of contact and therefore not involved in any maintenance 
treatment.  This was done by the other GPs and only when they were unavailable or if a 
drug related problem emerged during a consultation, he would take over.  Another 
interviewee commented that they used to treat drug users until recently when the Health 
Board introduced shared-care clinics and now all their drug using patients are referred 
there.  
 
3.2.2.3 Experience with Naloxone  
Overall, there was little experience with Naloxone as an antagonist for opiate overdose.  
Some interviewees had heard of the national programme but were not aware of details.  
One interviewee mentioned that he used Naloxone a long time ago before there were 
strict guidelines surrounding its usage; he only administered it in ER.  Another 
interviewee reported that he was involved in the original prescribing of Naloxone for 
home use many years ago.   
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One interviewee, who mentioned that he carries Naloxone in his medical bag for 
opportunistic delivery in the practice, has some patients that are involved in the 
Naloxone project through the shared-care clinic which gives him indirect access to 
Naloxone.   
 
Another interviewee, who was very much in favour of Naloxone distribution through 
general practice, reported that he has seen many drug users who had overdosed and 
were: 
 
‘...in extreme coma, and it just reversed immediately with Naloxone...’ (13) 
 
One interviewee with 21 years of experience in treating drug users reported that his 
practice did at one time have a national programme.  This was run by a substance 
misuse nurse who left and once she was gone, the programme was stopped.  There 
was no GP involvement in this service.   
 
Another interviewee reported that they have been doing Naloxone training in their 
practice for about a year and this is led by the psychiatric nurse.  In a different practice, 
an interviewee reported that he would occasionally prescribe Naloxone on the 
recommendation of a substance misuse nurse (from the substance misuse service), or 
because a drug user who had been prescribed Naloxone in the past, would come for re-
supply.  
 
Several interviewees had not heard about the national programme prior to being 
approached for the interview.  In this sense, one interviewee reported that he has 
approximately 60 patients registered as having substance misuse problems but has 
never prescribed Naloxone as a ‘rescue’ medication; he only heard about the 
programme when contacted for the interview.  Similarly, another interviewee with drug 
users in his practice said:  
 
‘I have not prescribed Naloxone as that specific prescription would be led by the 
specialist services. ....I have not heard about the Scottish Naloxone programme before 
speaking to you.’ (11)  
 
And again along those lines another interviewee mentioned that he works with patients 
on a methadone programme and has: 
 
‘....heard of the Naloxone programme, which is going [on] in Aberdeen I think and 
Lanarkshire’ (9) but has not yet prescribed it.  
 
One interviewee explained that while his practice does not provide direct treatment, they 
display posters and leaflets in the waiting area and will suggest that the patient makes 
contact with appropriate services.  
 
GPs who work in prisons were more familiar with the use of Naloxone and the national 
programme.  One of them reported that within the prison service, he provides inmates 
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with substance misuse services which include counselling, prescribing and dose 
adjustment.  Within this remit he has heard about the national programme starting and 
has prescribed Naloxone but not received any specific information.  In the practice 
where he works, he does not prescribe Naloxone as this is done through the substance 
misuse service.  Another interviewee was familiar with Naloxone in his practice and has: 
 
‘...actually discussed it with a couple of patients...two of them have expressed an 
interest...I got the feeling that there was quite a keenness to have it as widely circulated 
as possible within the drug misuse community so I’ve got no real problem prescribing 
Naloxone for some of the individuals concerned..’ (16).   
 
He did, however, mention that he felt slightly apprehensive to just write a prescription 
without having had a proper training about issues surrounding Naloxone. 
 
3.2.2.4 Willingness to participate in the National Programme 
A further topic which emerged from the interviews was the willingness of interviewees to 
participate in the national programme.  Most of the interviewees that were not already 
involved were in favour of participation, however, there was distinct uncertainty 
surrounding the programme and its delivery in primary care.  Responses given centred 
around the following areas: 
 
• Willing to participate but no need at own practice. 
• Willing to participate but unsure of what is involved. 
• Willing to participate but would like to see financial benefit. 
• Willing to participate but others reluctant to get involved. 
• Willing to participate after avoidable drug death. 
• Willing to participate but need clinical evidence of its usefulness. 
• Prison GPs already involved with Naloxone. 
 
3.2.2.4.1 Willing to participate but no need at own practice 
Several interviewees did not see the need for this in their own practice.  They explained 
that currently either no or only a very small number of drug users are registered and 
these would be referred to a drug misuse service.  However, one of them commented 
that if the national programme was rolled out in primary care as a new service, ‘he would 
be happy to learn more about it and if it seems appropriate......willing to participate.’ (1)  
This was echoed by another interviewee: 
 
‘I would be prepared to be involved if having read more about it, if I thought it was the 
right thing to do..... ‘(4) 
 
A similar opinion was voiced by another interviewee who commented that he knew 
several GPs who only have a small number of patients in their practice, and if a drug 
dependency problem comes into this, they would treat the patient to their best ability but: 
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‘...wouldn’t necessarily extend out to...more complex range of things....they would refer 
that on to the local drugs team...’ (13)  
3.2.2.4.2 Willing to participate but unsure of what is involved 
One interviewee, who has not had any involvement yet but would be prepared to 
participate, commented that he has to discuss this with the other GPs in his practice 
before committing.  This was echoed by other interviewees, one in particular 
commented that he would be keen to participate as he considers this to be a ‘good thing’ 
(9) but would have to discuss with colleagues prior to implementation.  Currently, his 
practice has Naloxone available and if a patient turns up in a severe overdose state, it 
will be administered but it is not routinely used and never prescribed as take-home kit; 
another interviewee who has patients that are involved in the Naloxone project (through 
another source) would be willing to participate in the prescribing and speaking to family 
and peers.  
 
One interviewee, who expressed an interest in the programme, mentioned that in his 
practice drug using patients are encouraged to attend Naloxone training sessions where 
they can learn about take-home supplies.  These training sessions are provided through 
the drug misuse service.  While he seemed to be keen on the programme, he did not 
think that prescribing through general practice was required: 
 
‘....we are directing people towards obtaining supplies from pharmacies and things like 
that.  I don’t see ourselves prescribing it directly to people, there doesn’t seem to be any 
particular need to do that, as far as I understand the programme.’ (10) 
 
This interest in Naloxone was expressed by many interviewees although it was evident 
that a lot more information is required: 
 
‘....there would need to be more detail of how that would be implemented in practices, 
and what that would look like for individual practices to sign up.’ (11) 
 
And:  
 
‘Yes, definitely.......but I would have concerns if it became something that the GP’s 
themselves had to deliver if there weren’t resources to do that, because it’s another 
time....’ (12) 
 
And:  
 
‘I like to think that Naloxone sounds like a good idea and certainly worth considering....’ 
(7) 
 
And: 
 
‘I think it’s....a really good idea....I don’t feel I have the expertise to deliver it.’ (12) 
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3.2.2.4.3 Willing to participate but would like to see financial benefit 
Three interviewees mentioned that they would be willing to participate if there was a 
financial benefit:  
 
‘If the financial aspects were favourable......then the motivation for being involved with a 
heavy time commitment group of patients, might...be attractive.’ (11)  
 
Similar comments were given by different interviewees: 
 
‘...we’ve had a few discussions.....about this Naloxone programme....it takes up quite a 
lot of time, so what we decided is, we would be quite happy to participate if there are 
financial incentives...’ (9) 
 
‘GP’s can get paid additionally for dealing with drug users...and we do, we get quite a lot 
of income from that, although I have to say, you know, that more of less covers the 
doctor time and not much else.’ (13) 
 
3.2.2.4.4 Willing to participate but others reluctant to get involved 
A couple of interviewees mentioned that while they would be interested to participate, 
they are concerned about the lack of interest of their colleagues:  
 
‘.....and my other colleagues are not very supportive........My colleagues are just trying to 
not see any drug users at all; they would probably be uncomfortable with lack of 
knowledge.’ (6) 
 
Another interviewee offered to arrange an interview with one of his partners who does 
not want to treat drug using patients and opposes Naloxone administration.  He later e-
mailed to say that this person had actively declined to discuss his negative views.   
 
The same message came from another interviewee who said: 
 
‘...some of my colleagues are uncomfortable dealing with them, I don’t know the 
barriers, just...they are uncomfortable...they can’t deal with that.’ (14) 
 
3.2.2.4.5 Willing to participate after avoidable drug death  
One GP mentioned that they recently experienced a drug death in their community 
which may have been preventable if Naloxone had been available: 
 
‘I think it would be a really good idea, we’ve had a death, quite recently, from an 
overdose in our practice..........If he had Naloxone, that guy would not have been dead...’ 
(7) 
 
3.2.2.4.6 Willing to participate but need clinical evidence of its usefulness 
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It was also highlighted that, before implementing a new service which requires additional 
resources, there have to be: 
 
‘....clear clinical benefits......’ (11)  
 
The same concerns were mentioned by other interviewees: 
 
‘I’m not a specialist...but from my understanding there’s been studies done that show it 
does reduce overdose death...if there is good evidence then I would be supportive of it.’ 
(4) 
 
And: 
 
‘..if you are looking after drug users, you...have to be convinced by the evidence, that by 
providing maintenance drugs you are doing more good than harm.... there’s the same 
question about Naloxone.....you have to be convinced that giving people an extra drug 
to limit damage is going to do more good than harm ....and then I think it’s worth doing in 
practice.’ (15) 
 
3.2.2.4.7 Prison interviewees already involved with Naloxone 
Several prison GPs were interviewed for this study and one of them gave insight to 
issues involved in the national programme: 
 
‘We...train our patients who are homeless or in temporary accommodation...families, 
friends, partners have often split from them........and then [they]...become our 
patients.....prime focus is on...patients themselves, although information to be effective 
is no good for the patient themselves.  They are encouraged to make others around 
them aware that they have this [Naloxone]...the focus was still mainly on educating the 
patient, and the patient was then to make others aware that they had the Naloxone...’(2) 
 
Another prison GP commented that while he agrees in principle, he does not know 
enough about the programme to judge if it was better to have it delivered through 
general practice or through a specialist service.  In his involvement at the prison, he 
would have several counselling sessions with prisoners regarding dosage adjustments 
and risk reduction in terms of overdose throughout their incarceration.  This would not 
necessarily result in a Naloxone prescription at that time but it would give them an 
awareness of availability at time of discharge.  Part of the problem is that most prisoners 
do not consider themselves to be at risk:  
 
‘..I have yet to find one who thinks it will happen to them. Everyone has heard about it 
happening to other people.... but a number of prisoners have been agreeable to take the 
kit but they tend to think that they will never need it.’ (8) 
 
Another interviewee who works in a prison commented that inmates with an addiction 
problem will attend a short course prior to release to give them an awareness of the 
problem and at the same time receive a Naloxone take-home kit.  However, there is no 
27 
 
contact with family or peers and it is up to the inmate to relate this information to 
someone else after release.  
 
Another interviewee reported that in the past they did not stock large amounts of 
Naloxone in prison.  However, this was changed after an incident where a prisoner 
broke into the drug cupboard room; several prisoners overdosed and there was not 
enough Naloxone available at that time: 
 
‘...we did run out of Naloxone that time’ so ‘...now we have a stock of medication and 
also a number of the emergency pharmacies.’(14)  
 
3.2.2.5 Resources 
When implementing a new service, resources are often a factor which impacts the 
willingness to participate in this and therefore interviewees were asked if they thought 
that additional resources were required and the following range of views were 
expressed: 
 
• No additional resources required. 
• Unsure if additional resources required. 
• Additional resources required. 
3.2.2.5.1 No additional resources required 
Most interviewees did not think that they needed additional resources.  This was partly 
due to them thinking that this service should not be delivered through primary care.  One 
interviewee did not consider the service necessary for his practice as he has no drug 
using patients so additional resources would not be an implication for him.  Another 
interviewee felt that the current set up for his drug using patients where they have open 
access to recovery hubs and are encouraged to self-present are sufficient and there was 
no need to introduce this into primary care; hence no additional resources would be 
required.  
 
Another interviewee did not think that this service is something which needs to be overly 
resourced:  
 
‘These people are all fairly expert in injecting themselves anyway, so it would be a 
matter of producing a pack of some sort and giving them written information.’(7) 
3.2.2.5.2 Unsure if additional resources required 
Several interviewees were unsure if they needed any additional resources for the 
national programme because they were not the main decision makers in the practice or 
simply did not know what would be involved: 
 
‘I don’t really know’ (4), ‘I’ve got no idea....’ (5), ‘I don’t think we would need extra 
resources...’ (7), ‘I don’t think there’s anything particular that we would need... in terms 
of resources for us, I don’t think there’s anything we need.’ (10) 
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With this in mind, they quoted time constraints, lack of space and finding someone to 
deliver the service as factors which would require additional resources.  
 
3.2.2.5.3 Additional resources required 
Some interviewees did envisage that the introduction of a whole new service would 
require additional resources ‘for a couple of years, until we can get going, and running 
the service.’ (9) In the current environment, ‘things are getting tighter and tighter.....it’s a 
bit like spinning plates....it’s all held in there just by the effort of several people’ (13) 
 
And: 
 
‘....if you’ve got a patient coming in...the way to do this properly means that you have to 
take X amount of time and tick X number of boxes, the big issue there is time, and 
employing someone who can meet that time’ (11),  
 
‘...you would need somebody....who could do whatever training was required 
to...probably need to find out what was involved...’ (12)  
 
These responses all signify a lack of knowledge about the programme as a whole and 
there was a sense that further information was desired to outline all of the practicalities 
that will be involved.  
 
3.2.2.6 Opportunistic Naloxone 
During the interview it was asked how they might deal with a patient who presented for 
an appointment, for example, with a minor infection which requires antibiotic therapy.  If, 
during the consultation, the GP suspected that they were facing a drug user who may be 
at risk of overdose, would they address this appropriately?  Most of the interviewees 
were concerned that this was not within their level of confidence or, as in the case of 
prison GPs, not aware this service was offered out with the prison service and therefore 
would not approach patients about Naloxone in the practice, even if they did appear to 
have a drug user at risk of overdose.  Several views were expressed within this theme: 
 
• Not a scenario which would happen in my practice. 
• Approach clinical need and refer for drug problem. 
• Approach and deal with drug problem. 
• Assess if there is willingness to change behaviour. 
3.2.2.6.1 Not a scenario which would happen in practice 
Three interviewees said that they could not imagine this in their practice as none of them 
have drug users as a patient group.  Two of them work in small rural practices in fairly 
affluent areas where they know every patient.  While one of them has two patients 
registered for drug dependency, they get their prescriptions from the local drug misuse 
service and he has no involvement.  
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The other one commented that such a scenario would involve a new or temporary 
patient and prescribing Naloxone would not cross his mind.  If the patient wanted a 
methadone prescription, he would refer, other than that he would treat the patient to the 
best of his ability and:  
 
‘...be hoping they didn’t raise the whole drug misuse thing at all, because I wouldn’t be 
sure, I wouldn’t know, and if they did raise the whole drug misuse and were looking for a 
prescription for something, we’d say no...’ (1) 
 
This view also hints drug misuse is ‘off the radar’ of some interviewees.  Those 
interviewees that rarely come across drug users e.g. in rural practices do not feel 
informed or skilled enough to address issues that might arise with drug users generally 
and Naloxone is grouped with drug misuse.  
 
3.2.2.6.2 Approach clinical need and refer for drug problem 
Several interviewees did not feel that they have the skills or knowledge to deal with such 
a situation comfortably and would refer the patient to a substance misuse facility: 
 
‘If I knew exactly what to do I would treat them........I would mention that I run a clinic 
and....once we have the system set up with the Naloxone, I would of course include 
that.’ (6) 
 
Others mentioned that they would approach the situation, deal with specific clinical 
needs, possibly discuss methadone prescribing and then refer to a substance misuse 
clinic where they can get Naloxone: 
 
‘...and if there are specific substance misuse problems....you may refer them onto more 
specialist services, or the practice substance misuse clinic’ (11) 
 
Some interviewees mentioned that while they did not feel comfortable with Naloxone, 
they would deliver an opportunistic brief intervention if they considered this to be 
appropriate.  
 
3.2.2.6.3 Raising the issue of drug use 
One interviewee from an inner city practice which has close links to addiction services, 
reported that all patients are routinely asked about drug use at the time of joining the 
practice; therefore it is unlikely that drug problems will be picked up ‘by coincidence’ (5). 
If a patient has ever used drugs of any kind, this will be discussed and if they are regular 
drug users: 
 
‘The advantages of having Naloxone available....will be discussed and....will be strongly 
encouraged to have Naloxone at home. ‘(5) 
 
Another GP reported that if a patient appeared to be a drug user but has come for 
something else, he will ask outright if they are taking heroin:  
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‘Often you can tell, sometimes people turn up at their doctors stoned, they are usually 
not in a great frame of mind to consider doing anything, and they usually do not have 
much interest in engaging with anything at that particular time.’ (7).  
 
One interviewee stated that such a scenario may offer an opportunity to mention 
Naloxone, and if required, it can be supplied opportunistically.  
 
3.2.2.6.4 Assess if there is willingness to change behaviour 
Another interviewee mentioned that this would be confronted and assessed to see if the 
patient wants to change their drug using behaviour.  
 
‘if they have no intention of changing their lifestyle...I would, maybe give them some very 
brief advice and move on, but if they indicated that they wanted to change, or get help, 
then I would probably refer them to the drug and alcohol teams initially.’(12) 
 
Once again, these comments highlight the need for better information and training so 
that general practitioners can gain confidence in treating drug using patients.  
 
3.2.2.7 Models of delivery in practice 
Interviewees were asked how they could envisage the national programme to be best 
delivered in practice.  Interviewees generally had difficultly answering this question as 
there seemed to be some confusion to its scope and delivery.  Responses fell into two 
distinct categories:  
 
• A specialised substance misuse service  
• Non-specialist (GP, nurse or specialist worker)  
 
3.2.2.7.1 A specialised substance misuse service 
Many interviewees seemed to think that the national programme was a service which 
should not be delivered in primary care; they were of the opinion that existing models of 
shared-care programmes and substance misuse services were sufficient and there was 
no need to change this.  For example: 
 
‘...if practices are already signed up to a service where they are looking after drug 
addicts, I can’t see any problem about the prescribing and training and administration 
being built onto that...’ (1).  
 
‘The way that it’s done in the practice just now.......is between the GP and drug support 
workers, so I would think that it would be reasonable to be doing it along the same kind 
of lines..’(4)  
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‘I think the best mode of delivery is to convey to patients that it is through the addiction 
support...and then the kit is provided by the local pharmacy....it would not be delivered 
through our practice.’(5) 
 
One GP was of the opinion that drug misuse is a psychiatric problem and should be 
referred and treated in secondary care as an addiction disease.  In his practice during a 
10 minute consultation, there are: 
 
‘A lot of issues coming up...with drug users...we really we struggle very, very much to 
even profile the bare minimum of that and at the moment, Naloxone...is not on the 
agenda..’ (13) 
 
The view that it should be dealt with by specialists also extended to the delivery of 
training for drug users/families on administration and emergency care. 
 
‘When it comes to the training itself it is probably not directly the role of people within the 
practice... far better to have someone coming in from outside...’ (10) 
 
‘I can see the benefits of a more specialist role.......I think that is a far more sensible 
approach than for example these patients being dealt with randomly by random GP’s 
who have just a little bit of knowledge about this..’ (11):   
 
3.2.2.7.2 Non-specialist (GP, nurse or specialist worker) 
Several interviewees thought that anyone from clinician, nurse or specialist worker could 
deliver this service; the key issue here was that the person who has the most contact 
with the patient should look after the training and Naloxone prescription.  One 
interviewee thought that a nurse with special interest should work with a GP in close 
enough proximity so that: 
 
‘...they develop some sort of good working relationship...and confidence in each other’s 
approaches.’ (15) 
 
Others commented that everyone involved with the patient should be trained up on the 
programme.  This was echoed by another interviewee who suggested that a GP with 
specialist interest, one of the nurses or practice staff could do the training and: 
 
‘...have a separate side clinic to invite in all the patients at risk of DRD to see if they 
would want to get Naloxone prescribed.’ (3) 
 
Another GP commented that at their practice two specialist nurses and a voluntary 
organisation have first contact with drug using patients; and after an initial assessment, 
further treatment would be through to the mental health department. He commented that 
none of his colleagues are keen to be involved (6). 
 
A further suggestion for delivery was to invite drug using patients in for a longer 
appointment or in a group with families and discuss this.  It should be delivered through 
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a specialist nurse.  He mentioned that if a patient requested Naloxone, he would offer 
further information and then refer to the specialist nurse.  
 
Another suggestion was that it should be provided either in general practice or specialist 
services because: 
 
‘..there may be some patients who are genuinely medically well, and they only contact 
the health services through their methadone prescription....if you wait for them to come 
along to see us, they may never come.’ (8) 
 
Equally it should also be provided on an opportunistic basis, because: 
 
‘...the trouble is if you make it either or, you could miss out a group of patients who could 
potentially benefit...’ (8) 
 
Two interviewees had very strong views about the programme being GP and not nurse 
led.  One of them commented: 
 
‘..it’s not going to be nurse led [meaning specialist substance misuse nurse], we may 
take in advice of substance misuse nurse, if possible, but it’s going to be GP led.’ (9)   
 
This opinion was contrasted in another practice where the GP favours a specialist nurse 
over the GP as they would be:  
 
‘...involved with the patients anyway...they know them, and can assess whether it’s 
appropriate for them, and then can deliver it, and they have longer appointments with 
them....and probably more expertise in it.’ (12) 
 
One interviewee who has many years of experience in treating drug using patients, 
works with a model where GPs do the prescription, psychiatric nurses do the referrals 
and then a consulting psychiatrist visits the practice once a month for a consultation with 
the referred patients; GPs will then be advised on how to best treat drug dependent 
cases with additional mental health problems.  Currently, this model does not include 
Naloxone provision but if it is to be implemented in primary care, this particular 
interviewee felt that everyone should be involved and it: 
 
 ‘...has to be opportunistic....linked in with other services....you have to take the 
opportunity because you don’t necessarily get people queuing up and...saying, I haven’t 
got my Naloxone kit, and the only logical place to do it is, to do it when you prescribe 
methadone because that’s the one time we know...the patient is listening to us..’ (13)  
 
Again, these varying opinions highlight the fact that more information is needed and 
models of delivery should be presented in detail so that GPs can decide if and how 
Naloxone would fit into their current practice.  
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3.2.2.8 Barriers to Naloxone  
A key objective of this study was to identify barriers for GPs to engage effectively with 
the national programme.  More specifically, one of the objectives was to identify real and 
perceived barriers to the delivery of current/proposed models of care.  All interviewees 
were asked about barriers which they could foresee.  Responses given were: 
 
• this is not part of GP package, 
• training issues, 
• reluctance to prescribe drug which will be given by another person, 
• lack of education, 
• reluctance to treat drug users, 
• Naloxone can be seen as a safety net, 
• storage of Naloxone, 
• time, space and money. 
 
These are presented in more detail below. 
3.2.2.8.1 Not part of the GP package 
It was noted that substance misuse has not traditionally been core GP medicine.  The 
GP contract of 2004 contained a separate element which started to recognise and 
remunerate the effort that went into the care of substance misuse problems.  Various 
quality criteria had to be met by the GPs to be able to claim that remuneration.  For this 
reason several interviewees felt that Naloxone should be part of the direct enhanced 
service package, otherwise a significant proportion of GPs who do not want to get 
involved will opt out.  One interviewee said: 
 
‘...well, we don’t have to do that, so we don’t want to get involved in that...’ (2) 
 
This was echoed by another interviewee who works in a very small rural practice; he 
would not sign up to the national programme because it was not needed for his practice 
and it would be just another thing: 
 
 ‘...hoisted on us, we’ve got enough work as it is’. (1) 
 
A comment by another interviewee reflected that this issue should be dealt with at 
Health Board level:  
 
‘...If financially, on a national level, this becomes a directly enhanced service...and is 
mandatory for practices, then that immediately puts a different spin on the whole 
implementation question. ‘(11) 
 
And another interviewee commented: 
 
‘...there are no additional resources to prescribe Naloxone, or to talk to patients about 
Naloxone, it’s not part of the enhanced service contract...’ (13) 
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The same GP highlighted that because patients do not know about it, they do not ask for 
it, so this makes it even less interesting from the GPs side: 
 
‘Patients have come in saying they’ve got a pain here, they’ve got a pain there...they 
need some methadone....they want to talk about this...they don’t come in saying please 
give me some Naloxone.’ (13) 
 
These comments suggest that if GPs can avoid involvement they will, on the basis of 
need and managing workload. 
 
3.2.2.8.2 Training 
Appropriate Cardio Pulmonary Resuscitation (CPR) training, which is not part of the 
primary care structure at a small rural practice, was perceived as another barrier.  One 
practice has a limited number of staff training places each year and it would be difficult 
to resource the training for all members of staff.  However, he felt that if the programme 
was rolled out and included CPR training, it may also have a positive impact on other 
areas such as cardiac rehabilitation.  This concern with CPR training was mentioned by 
several interviewees and one in particular said:  
 
‘I would suggest that this would need to be thought through centrally, so that there are 
programmes where people could be referred, hopefully locally, for CPR training’ (1) 
3.2.2.8.3 Reluctance to prescribe drug which will be given by another person 
Another perceived barrier noted was the reluctance to prescribe an injectable 
medication to ‘chaotic’ drug users.  One interviewee commented that as Naloxone would 
not actually be used by the drug user himself but by somebody else, other people have 
to be engaged and this may be difficult as drug users often have a limited and chaotic 
social circle.  This interviewee thought that it was:  
 
‘...a bit pointless, I’m prescribing it for you, but you are not going to be the person to 
administer it.’ (3) 
 
This was echoed by another GP who said: 
 
‘But the most important thing is the carers, and their willingness and that is what we see 
as a barrier.’(9) 
3.2.2.8.4 Education 
Several interviewees commented that they believed that these challenges can be 
overcome by education but this was seen as a further barrier as it may be difficult to 
engage GPs to attend educational sessions; they may not engage out of ‘fear of looking 
like an idiot.’ (6).  It may also take up too much time to engage in the Naloxone 
education (7) and this may be a barrier, similarly ‘you could have an individual GP 
whose skill level or knowledge base doesn’t match up with what’s needed..’ (11)   
According to another interviewee: 
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‘A substantial number of GPs will not want to be involved with drug users, because they 
work in an area where there isn’t a lot of drug use and they don’t feel they have the 
skills.‘ (13) 
 
One interviewee reported that many GPs receive a large number of messages each day 
about ‘what they should and what they shouldn’t do’ from various disciplines and 
sometimes is difficult to distinguish between what is important and what is not important.  
In this sense, GPs need to be educated and convinced that this is something important 
to do: 
 
‘...because GP’s are largely motivated by the interest in the patients, and what they think 
will benefit them most in that 10 minute consultation...and often overdose....is a 
conspiracy of silence...it’s not going to happen...they are not at risk.’ (12) 
 
Another interviewee who is experienced in Naloxone distribution through prison work 
suggested that there should be clear guidelines: 
 
‘...saying...the things to do, a, b and c, and then they shouldn’t have a problem dealing 
with it like they do with any other illness, they should get proper lectures and 
education...even if they refuse to treat drug addicts, this is a drug addict emergency, not 
anything else, and that’s a part of the service to the community and should be included.’ 
(14) 
 
And another GP would like to see: 
 
‘...an on-site presentation, possibly at our own drug misuse clinic would be really useful, 
and we could do that, that way you could circulate the information to a wide number of 
people and see what their level of interest is...’ (16) 
 
3.2.2.8.5 Naloxone can be seen as a safety net 
A big concern was that if drug users have access to Naloxone, they might be tempted to 
use more heroin ‘as a kind of safety net’ and it may encourage them to use heroin along 
with methadone.  
 
‘People may think it is safe as long as I’ve got the Naloxone there.’ (7) 
 
One interviewee, who has had personal experience with Naloxone, was concerned that 
the effect of Naloxone wears off, a further dose may be needed and it can still result in a 
potentially fatal overdose:  
 
‘...so I think there would be a concern that potentially somebody might get a single dose 
of Naloxone and an ambulance not be phoned and it could potentially then be 
dangerous.’ (3) 
 
And another interviewee was concerned that: 
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‘...there is always the risk that you will get people who previously had been frightened to 
take heroin, when maybe they were taking methadone as well, that if they got Naloxone 
around, they might feel it is safer to do.’ (7)  
 
And along those lines, another interviewee commented that while the drug using patient 
may see Naloxone as a safety net, family/peer may not be willing to be involved, hence 
this perceived safety net is dangerous as no one would be available to give Naloxone in 
case of overdose.  
 
3.2.2.8.6 Reluctance to treat drug users 
Practices that do not prescribe methadone may feel that engagement with the national 
programme is too close to becoming involved with drug users.  This opinion was voiced 
by several interviewees, one of whom said: 
 
‘A couple of my partners are not happy at all dealing with people who are on drugs’. (9) 
 
A similar comment relating to reluctance to treat drug users was made by another 
interviewee:   
 
‘Not wanting to treat drug users....it’s got to do with their own attitude....which is pretty 
shameful, but there you go.’(10) 
 
And: 
 
‘...an individual GP prejudice...that they may not want to be involved with that type of 
patient...’ (11) 
 
However, according to one interviewee, even if GPs do not want to treat drug users, 
they can give out a possible life saving treatment: 
 
‘...they could say well, there’s nothing I can do for you, other than refer you, but then 
here you can do that to make yourself safer...’ (6) 
 
Similarly, the characteristics of drug users were seen as another barrier by several 
interviewees as these could be quite disruptive individuals with behavioural problems 
which could affect other patients in the waiting area.  Some GP’s may not have the 
particular premises to accommodate this: 
 
‘...those people might be concerned it might change the atmosphere in the practice, if 
they had more of these people coming in, it might concern other patients...’ (12) 
 
This was expressed by another interviewee who commented that drug dependant 
patients have an overriding need for drugs and therefore they cannot be trusted:  
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‘If I started treating a drug user here, I’m not particularly keen to do it, because we have 
such a cosy safe set up, patients come in and out of the rooms, personal property is left 
around the place safely....so it alters the things quite fundamentally..’ (15) 
 
One interviewee simply stated that as he has no known drug users registered in his 
practice, and could not imagine anyone requesting Naloxone; therefore there are no 
barriers for him as his patients only come for non-drug related problems.  He would 
however be willing to: 
 
‘...keep some Naloxone there, in our emergency cupboard’, just in case it was needed 
unexpectedly.’ (14) 
 
3.2.2.8.7 Storage of Naloxone 
Several interviewees mentioned storage as another barrier (8, 3, 16); one of them felt 
more comfortable to just prescribe Naloxone but not storing the kit as he was concerned 
this could:- 
 
‘...create a kind of surge of demand, especially when it’s launched. Also, I don’t know 
where it’s going to be stored, and who is going to be using it...’ (8) 
 
And along the same lines one interviewee raised his concerns about costs of the unit 
and storage and duration of viability, not just at his practice but also at the patient’s 
house:  
 
‘I think they [the drug using patient] are probably more used to looking at Naloxone 
administration through Pulp Fiction, than they are through educational 
programmes...and I’d probably need a little bit more information on that.’ (16) 
 
3.2.2.9 Time, space and money  
Time and lack of resource was mentioned by several interviewees as a barrier:  
 
‘...time is one barrier...’ (7) 
 
Another interviewee said:  
 
‘...some of the barriers may be physical space, so for example our practice is quite 
limited in building size and room availability......There may [be] time and cost constraints 
as in, do we have time, can we afford to have someone provide this service..’ (11) 
 
This was also mentioned by a third interviewee:  
 
‘...I suppose worries about the time implications, if it was deemed to be something that 
GP’s had to deliver without any extra resources... I think the main thing would be the 
resource issue.’ (12) 
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While there seems to be a lot of confusion surrounding content and delivery of the 
national programme, three comments of sympathetic interviewees summed up what 
they viewed as the importance of it all: 
 
‘drug deaths have gone up again and the more that this is out there, the more chance of 
giving people a second chance to get better, you can’t help dead drug users really, can 
you?’ (3) 
 
And: 
 
‘...at the end of the day, they are all somebody’s children... it’s very important that GP’s 
are pro-active and sympathetic in helping...as much as possible.’ (5)  
 
 ‘...and trying to make them safer in an environment where they may use illicit drugs’. 
(10) 
 
One interviewee thought the biggest problem with the national programme is that it is an 
antidote for heroin which was ‘yesterday’s problem....tomorrow’s problem is different so 
we are dealing beautifully with a world that no longer exists.’ (16). 
 
3.2.3 Analytical themes 
In addition to the themes emerging within each topic there were some analytical themes 
that emerged across all themes.  These are described as: lack of knowledge; 
‘typecasting’; ‘off the radar’ and negative attitudes.  Typecasting refers to the immediate 
grouping of Naloxone as a specialised substance misuse service and linked to this is the 
‘off the radar’ theme in which some GPs have no need to ever think of injecting drug 
users and the potential need for Naloxone.  This is more likely to apply to practices that 
do not think they have drug users on their practice lists.  Negative attitudes were clearly 
evident in some interviews and questionnaires.  These themes will be integrated into the 
following discussion of findings. 
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4. Discussion  
 
4.1 Summary  
This research identified some awareness of the national programme, but very low 
current levels of involvement by GPs sampled (3.4%), little involvement in distributing 
information (<20%), and limited awareness as to who the local Naloxone lead was (8%).  
However there was tentative willingness to be involved in Naloxone prescribing with half 
of respondents willing to provide this to drug users or their friends/family, although both 
interviews and the survey indicated that GPs did not currently feel sufficiently skilled or 
knowledgeable to provide Naloxone.  There was a strong need evident for information 
on DRDs, risk factors, the prescribing and use of Naloxone, all of which should be 
evidence based.  A key barrier identified was the typecasting of Naloxone prescribing as 
a specialist service that only specialists can provide. 
 
Further analysis found those with some, but not all, specialised drug treatment training 
had greater awareness of some of the risk factors for DRD (being an injector, recently 
released from prison or recently completed detoxification). 
 
When asked what might enable the expansion of the national programme into primary 
care, the respondents rated the following factors as ‘very important’: having supporting 
evidence 89.7%; appropriate training 82.8%; it must be on the local formulary 67.2%; 
that practice nurses should be trained 52.3%; GPs should be paid 43.5%; it should be 
part of the quality and outcomes framework 14.7%.  From interviews, it became 
apparent that GPs were not really aware of what Naloxone provision may involve. 
 
4.2 Strengths and weaknesses  
The key strength of this project was that the use of mixed methods allowed both national 
representation and breadth of information alongside complementary in-depth exploration 
through interviews.  The survey sample was nationally representative to ensure Health 
Board variations were accounted for.  The response rate to the survey was initially lower 
than anticipated, but ultimately boosted by the short questionnaire sent as a third 
reminder.  Generating a good response rate from GPs for postal questionnaires is very 
challenging.  This was anticipated and several steps were taken to boost response and 
helped achieve the final response of 55% which compares well with more recent GP 
survey response rates.11   
 
Regarding how representative the sample was of the GP population, the sample 
compares well with the national GP population, in which 47.8% are male.14  In addition, 
a previous survey of Scottish GPs also found the biggest proportion working in towns 
(41.5% compared to 44.1% in this survey), with similar proportions located across City 
Centre, suburban or rural practices.11 
 
The use of the short questionnaire to boost response and the data available also raised 
some interesting methodological considerations.  Chi- squared tests were conducted to 
determine whether the respondents to the short questionnaire were different from the 
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main (long) questionnaire respondents.  Some differences were noted: more females 
responded to the short questionnaire (although not significant) but these GPs were also 
more likely to be treating drug users.  Gender differences were also noted in the 
response to some questions i.e. female GPs were more aware of psychological stress 
as a risk factor.  These findings may have no relevance to the national programme.  
However, findings may be indicative of gender difference in the GP population that 
requires wider reflection and possibly further research. 
 
Telephone interviews had been previously used by the research team and were 
considered to work well with GPs who were generally focussed, efficient and articulate 
in their responses.  This made the process more efficient overall.  However, there was 
difficulty contacting and scheduling GPs to arrange times for interviews.  On the plus 
side, if an interview had to be postponed or cancelled (as happened on several 
occasions) it was better by phone than the researcher wasting a journey to a practice.  
Obtaining the specialist and prison sample was relatively simple as researchers could 
draw on contacts and resources in the team.  However, the non-specialist sample used 
the Primary Care Research Network and did not yield as many potential interviewees as 
hoped (less than our target of 12).  This may be indicative of the general difficulties in 
engaging non-specialist GPs in substance misuse related issues. 
 
Unfortunately, there was a gender imbalance in the interview sample.  Only two female 
GPs were actually interviewed although six were approached, and five had agreed but 
the interview could not be conducted in the timescale.  There is some evidence that 
gender can influence GPs’ level of sympathy towards drug users generally11 and one 
study has shown that female GPs with experience of DRD on their caseload showed 
greater prevalence of grief-related reactions.15  This indicates that if the sample included 
more females, there may have been slightly different views.  However, this was driven 
by the response to invites to participate.  A longer timescale would have allowed a 
proactive approach to recruiting more female GPs. 
 
4.3 Consideration of key findings 
 
4.3.1 Experience with treating substance misusing patients and Naloxone 
The proportion of the survey respondents currently treating drug users (47%) was 
comparable to a previous Scottish survey (43.7%) 6.  This indicates the survey response 
was representative of the GP population in Scotland in this respect. 
 
The level of current experience in the national programme was very low with only six 
individuals being involved.  Interviews also sought information on whether participants 
had any experience specifically of Naloxone prescribing.  About half of interviewees had 
some experience but this was not generally recent or part of the national programme.  
Only one had actually actively prescribed it for potential emergency use. 
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4.3.2 Awareness of DRDs, risk factors and the National Programme 
The knowledge of the number of DRDs in Scotland was surprisingly poor considering 
how much publicity this had received in the recent press; coincidentally, there had been 
considerable media coverage on the radio and in the press the week before the initial 
mailing.16 Despite this potentially heightened awareness, a considerable proportion of 
GPs surveyed (42.5%) did not know the correct number of DRDs in Scotland.  The 
number of DRDs has been increasing year on year and was over 500 in 2011 (and 2008 
& 2009).1 Only 12% correctly categorised the number in the 500-750 range.  Even if we 
generously assume those answering in the wider range of 250-750 have some 
knowledge this still leaves 69% that clearly did not know. 
 
Confidence in identifying and addressing overdose risk was low with just 24% GPs 
agreeing they felt sufficiently confident to do this at the time of this survey.  There was 
clearly a knowledge gap with 60% wrongly identifying people under 24 years as being at 
increased risk.  Other known risk factors were correctly identified by the majority of 
respondents, but there was less certainty in some factors, namely in those who have 
used illicit drugs for a long time and those who have recently been on a detoxification 
programme.  These are clearly factors that should be covered in any training that 
derives from this study. 
 
Almost two thirds of respondents had heard of the national programme, mostly from 
NHS Communications.  This is encouraging as it indicates that NHS Scotland has had 
some impact in trying to broaden awareness.  Unfortunately, when combined with the 
lack of knowledge on DRD risk factors it appears that awareness is at a very superficial 
level in which GPs have heard of the programme but perhaps not felt the necessity to 
get more involved.  This is supported by the few respondents (just 8%) who knew who 
their local Naloxone lead was or who provided information on Naloxone.   
 
4.3.3 Attitudes and willingness to participate in the National Programme  
There was clear uncertainty from survey and interview data about whether general 
practice was a suitable place for the national programme.  However, there was also 
willingness in that almost half were prepared to prescribe Naloxone and explain it to 
those at risk (or family/friends).  A fifth of respondents were definitely not willing and 
there was a relatively high proportion that answered ‘unsure’ to this specific question on 
willingness which indicates that they may be willing if certain requirements were fulfilled.  
Reasons given for being unsure were similar to those who stated that they were 
definitely not willing and were either around information/training needs or because all 
drug misuse services are managed by someone else e.g. another GP who is a specialist 
or the specialist drug treatment services.  These views that ‘someone else does this’ 
were very much echoed in interviews in which there was clear ‘typecasting’ of Naloxone 
prescribing with drug treatment services.  This was also evident in the NHS Health 
Scotland scoping exercise of Health Board involvement in which the lack of GP 
involvement was put down to local GPs deciding to opt out of care of drug users.13  This 
is discussed further under ‘Models of Delivery’ below. 
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In the survey, GPs were asked whether they believed general practice based distribution 
of Naloxone was essential to reduce DRDs.  Half of respondents were uncertain 
indicating again that they still need more information to convince them that they have a 
role to play rather than leaving it to specialist practitioners and services.  This was again 
further echoed in interviews in which non specialist GPs tended to frame their responses 
to questions around whether they would deliver Naloxone within their current set up for 
substance misuse services.  For example, several said there was no need for them to 
do it as others covered substance misuse.  This is further evidence of typecasting of 
Naloxone as a specialist service. 
 
Interview data also suggested that practices that do not prescribe methadone may feel 
that engagement with the national programme is too close to becoming involved with 
drug users more generally and they have actively decided not to do this.  This strongly 
indicates an underlying attitudinal barrier in parts of the GP population.  
 
A strong emerging theme was that of negative attitudes towards drug users which could 
be interpreted as the stigmatisation of drug users using current definitions.17 This is 
linked to the other emerging themes of typecasting of anything to do with drug misuse 
as a specialist service.  It appears that some GP’s may be rather too keen to ‘offload’ 
what is perceived as a difficult group in their entirety to specialist services rather than 
considering the non-specialist care that is also required and whether overdose 
prevention is part of this.   
 
The existing literature on GPs attitudes to treating drug users is old and this evidence 
suggests attitudes may not have improved over time.  This is in contrast to pharmacists 
who have demonstrated significantly more positive attitudes to treating drug users over 
time that is associated with their increased involvement and experience.18  Training GPs 
in drug misuse is known to improve attitudes.19  Indeed this study also indicates those 
with more training as likely to be more willing to provide Naloxone to drug users. This is 
considered further under enablers (section 4.3.5.2). 
 
Three interviewees mentioned that they would like to see a financial reimbursement to 
deliver a Naloxone service.  Others noted that it fitted into the substance misuse 
enhanced care package and this could ‘easily’ be added to that. 
 
As the interview sample was purposively sampled to include those more likely to be 
involved and informed (i.e. specialist and prison GPs) there was more experience of 
treating drug misusers.  The main motivating factor in one GP practice wanting to 
provide Naloxone was the experience of what was considered an avoidable death of a 
patient.  This finding concurs with other evidence in Scotland that experience of a DRD 
on the caseload of staff does cause a grief related response.15 It may be that this type of 
experiential evidence could be used to motivate others to participate.  
 
4.3.4 Models of delivery in practice 
Two models were presented in the survey and respondents were asked to note their 
preference.  The preferred model was one in which GPs only prescribed and someone 
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else delivers the training component.  Specialist services in the form of specialist nurses 
were the preferred people to deliver the training component.  There was little 
enthusiasm evident to involve practice nurses. 
 
There were very split views of whether group or ‘one to one’ delivery was preferable.  
However, the majority thought the training intervention would need to be 20-30 minutes.  
Those preferring a brief intervention did consider opportunistic delivery to be preferable, 
although opinion was split.  The interviews specifically probed the idea of opportunistic 
Naloxone if a GP found a patient was a drug user (e.g. when consulting for something 
else).  However, this scenario was perceived by many GPs to be unrealistic.  For some, 
this was because they said they know all their patients and see such an event as 
unlikely.  For others, they said all drug users were seen by specialist services.  Thus, 
there was a sense that this was off their radar and they were blinkered to the possibility 
as they were not used to managing drug users.  This has implications for the potential of 
an opportunistic, brief intervention type of delivery as considerable information would 
need to be imparted on the risks of DRD to even raise this issue in many GPs 
consciousness. 
 
Other models exist already in parts of Scotland: for example in Aberdeen a pharmacy 
prescribes Naloxone and training is provided by a specialist needle exchange.  One 
interviewee had experience of this system which was why he would simply refer people 
at risk to the pharmacy.  Although this was perceived by the individual to work well, it 
was not explored in any depth and no other interviewees suggested such a model.  
However, there was concern expressed about storage and pharmacy dispensing from a 
standard prescription was perhaps not being considered. 
 
It was noted in interviews that the intervention could be provided by a range of health 
professionals, not just GPs but specialist nurses who may or may not be working 
alongside GPs.  This highlights the point that every healthcare professional that has 
contact with drug users should be aware of reducing overdose risk as a priority.  There 
is a danger that there could be an assumption that someone else is addressing this 
therefore ‘I do not have to’.  The only way to avoid drug users falling through these 
potential cracks is for every health professional (specialist services/nurses, general 
practitioners and potentially pharmacists) to review the risks of DRDs with individual 
drug users as they present. 
 
4.3.5 Barriers and enablers to GP delivery of the National Programme 
4.3.5.1 Barriers 
Barriers were explored in detail during interviews.  A range of barriers was raised: lack 
of skills/training/information which is discussed in detail below under enablers; believing 
this was not part of the GP package (as has been discussed already); safety concerns; 
attitudinal barriers; time restrictions; money issues and practical concerns over storage, 
space etc. 
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Concerns were expressed in interviews that drug users might actually engage in more 
risky practice by knowing Naloxone was available.  However, this was also explored in 
the survey and just a quarter of respondents agreed with this.  Although a minority, it is a 
sizeable minority and should be addressed in any subsequent training.  A further 
concern was that people might delay calling for an ambulance if Naloxone is 
administered.  However, it is part of the training that accompanies Naloxone distribution 
that an ambulance is always called and the reasons for this are explained.  Many 
participants will not be aware of this as they are not familiar with the existing training.  
 
The stigmatisation of drug users was touched on above under attitudes.  Stigmatisation 
of drug users has been considered in detail in recent years.  The UK Drug Policy 
Commission (UKDPC) explored how stigmatisation of drug users manifests itself.17 The 
UKDPC report acknowledged that health professionals can stigmatise drug users and 
these findings support that view.  The author, Lloyd, concluded that viewing drug misuse 
as a health issue rather than a crime resulted in less stigmatisation.17 This approach 
would complement these findings in that GPs want to preserve life and therefore 
emphasising the lifesaving nature of supplying take-home Naloxone could be used as a 
way of convincing GPs to provide this intervention to people at risk. 
 
Attitudinal and time barriers clearly exist and are difficult to address.  Education and 
training are one way to overcome attitudinal barriers but there is a challenge in making 
such people attend and the training might need to be taken to them.  However, there 
may also be a need to try to work with GPs who do not want to treat drug users or do 
not feel they have the time.  Opportunistic Naloxone prescribing with a brief intervention 
to those at risk could be delivered without much commitment to further involvement but 
only if these GPs were convinced it would be sufficiently safe and could save lives.    
 
Practical barriers around storage and space are an issue that could be addressed 
through training.   
 
One further barrier that was raised in interviews was that drug users themselves are not 
interested in discussing their personal risk of a DRD because they do not consider 
themselves to be at risk.  There is some supportive literature around this concept given 
that 94.5% of fatalities were considered to be non-deliberate.20 This barrier, whether real 
or perceived, needs to be addressed in GP training.  
 
Some of the barriers raised by the interviewees are issues that are already addressed in 
the available training. 
4.3.5.2 Enablers 
Enablers were explored in the questionnaire by asking about the relative importance of a 
range of factors to consider when implementing the national programme.  Training and 
the need for evidence supporting the national programme were considered very 
important by a substantial majority of questionnaire respondents.  The majority did not 
think delivery of the national programme should be part of the Quality and Outcomes 
Framework (QOF).  This is perhaps not surprising as inclusion in the QOF would be 
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strongly encouraging GPs to do something that many do not feel skilled to do or do not 
want to do. 
 
Training emerged as a key enabler from both qualitative and quantitative data.  Training 
is important to both impart information and increase skills.  The need for effective 
training of clinicians (not just general practitioners) was also recognised in the English 
pilots of a cascading model of training in overdose prevention and take-home 
Naloxone.21  The cascading model of training professionals in the English pilots proved 
challenging.22  From the findings in this study there were some key features training 
should have given the GP population.  Firstly, the strong need for information to have 
supporting evidence.  Only 1% of the survey respondents did not consider this 
important.  Interview data suggested that there was a need to appeal to GPs intrinsically 
caring nature by emphasising the key message that Naloxone is lifesaving.  Training 
also needs to be delivered sensitively as from interviews it was clear that some GPs 
might feel almost embarrassed by their lack of knowledge.  Furthermore it should not be 
assumed that GPs have any level of knowledge of how to administer Naloxone.  Even 
those who are used to working with drugs users have rarely been involved in Naloxone 
administration themselves or training others how to administer it. 
 
The survey gave useful information about the preferred training medium.  Approximately 
a third felt online resources would be useful and just under half preferred locally 
delivered training.  
 
4.4 Policy implications 
 
The delivery of the national programme in primary care will need considerable training to 
support it as already detailed above.  However, this research has raised other wider 
issues that policy makers might want to reflect on.  Firstly, allowing specialised GP 
services within the GP contract appears to have facilitated the non-participation of 
generalist GPs in caring for drug users.  Drug users suffer multi-morbidity and die 
prematurely from a range of health conditions as well as DRDs,12 thus they need 
general medical care as well as specialist drug treatment.  Findings suggest that general 
medical care may be underprovided which requires further assessment.  This is not only 
important to address the health issues of individuals, but also the delivery of the 
Recovery focussed drug strategy.7   Furthermore, such gaps in medical care potentially 
may impact negatively on health inequalities. 
 
The negative attitudes of some GPs may underpin the lack of willingness to provide 
Naloxone specifically but may also underpin the lack of willingness to have any 
involvement with drug users.  No recent published research has considered whether or 
not GPs in the UK stigmatise drug users as a patient group in this way and further 
research is required.  It is only by addressing stigmatisation of drug users that effective 
recovery-based services can be delivered. 
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5. Conclusions 
 
5.1 Conclusion 
This research has identified minimal awareness among GPs of the national programme.  
Current levels of knowledge and experience of DRD and of Naloxone use are low, and 
information needs are high.  GPs tend to classify Naloxone provision as a specialist 
service and therefore assume it is not part of their remit.  Even those with higher 
involvement of specialist training in substance misuse consider this a service that is not 
relevant to them.  However, there were tentative and encouraging signs that some GPs 
would be willing to be more involved in Naloxone distribution if certain enablers were 
addressed.  Most important of these was training which was recognised by GP 
participants as essential and the research identified some specific suggestions about 
what this should include.   
 
This research identified that negative attitudes towards drug users are a clear barrier to 
any GP care of this patient group that needs to be considered beyond the expansion of 
the national programme. 
 
Greater involvement of GPs in a generalist model of Naloxone supply as a basic 
lifesaving intervention, that is not confined to specialist services, might have a knock on 
benefit by giving them experience of this patient group that so many GPs currently 
distance themselves from.  By exposing GPs to this patient group on the specific matter 
of avoiding DRDs, attitudinal barriers may start to be overcome. 
 
 
5.2 Issues for consideration 
 
Training for GPs is essential prior to expanding the national programme into General 
Practice. 
 
5.2.1 Specific training issues 
1. A range of training and information resources should be available to meet the mixed 
needs of GPs.  Both online resources and local evening training sessions are 
essential. 
 
2. Targeted training by national programme trainers through visits to practices that are 
not part of a shared-care scheme, but situated in areas of known drug use, may be 
required. 
 
3. Negative attitudes towards drug users generally must be addressed to overcome the 
stigmatisation of this group. Further research is required to test novel approaches to 
changing entrenched negative attitudes.   
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5.2.2 Training should: 
• assume a low level of knowledge of drug use generally and Naloxone 
distribution and administration in particular, 
• cover practical aspects of Naloxone administration (who, how, where), 
• cover risk factors for DRDs, 
• address expressed concerns (risky use of Naloxone/not phoning for an 
ambulance). 
5.2.3 Models of Naloxone delivery 
• Enhanced care of substance misuse should include running Naloxone training 
sessions for known drug users in that practice.  (This could include working with 
specialist services if part of a shared care scheme). 
• All GPs should be made aware that Naloxone packs can be prescribed/supplied 
to any drug user considered at risk on an opportunistic basis.  It must be 
emphasised this is not a specialist service. 
5.2.4 General 
• Any communication, resources or training material for GPs regarding Naloxone 
distribution should emphasise: 
o that this is a lifesaving medication, 
o there is good evidence to support the national programme. 
 
• An in depth exploration of the stigmatisation of drug users by GPs (and other 
generalist health professionals) is recommended to enable both the reduction in 
DRDs and recovery based drug strategy to be delivered.  
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